Findings from an exploratory analysis from the INDIGO study evaluating the impact of VORANIGO on seizure rates and quality of life will be shared in a separate poster presentation The extended ...
BOSTON, May 31, 2026 /PRNewswire/ -- Servier today announced updated efficacy and safety results from more than three years of follow-up in the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) ...
Latest long-term analysis, including more than three years of follow-up data of patients with Grade 2 IDH-mutant glioma treated with VORANIGO ® (vorasidenib), will be presented in a rapid oral session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results